Neuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call
Rhea-AI Summary
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders, has announced its plans to release second quarter 2024 financial and operating results before the market opens on Monday, August 12th, 2024. The company will host a conference call to discuss these results at 8:30 a.m. Eastern Time on the same day.
Investors and interested parties can access the conference call via a live webcast in listen-only mode. Additionally, participants have the option to register for the call to listen via telephone. It is recommended that attendees join 10 minutes prior to the event start time.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, STIM gained 0.53%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2024 financial and operating results prior to market open on Monday, August 12th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/xsxbsaxh. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. In the United States, NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar is also indicated as a first-line, adjunct for MDD in adolescents 15 and older. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 6.4 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.
Investor Contact
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
FAQ
When will Neuronetics (STIM) release its Q2 2024 financial results?
What time is Neuronetics' (STIM) Q2 2024 earnings call scheduled for?
How can investors access Neuronetics' (STIM) Q2 2024 earnings call?
What is the focus of Neuronetics (STIM) as a company?
